We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for Dupilumab (rch) (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
Dupilumab (rch)
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Dupilumab is indicated as an add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) associated with type 2 inflammation.
Therapeutic area
Respiratory